The growth factor receptor-bound protein (Grb) 14 is an adaptor molecule of the Grb7/10/14 family with characteristic Between Plekstrin and SH2 (BPS) domains serving to avidly bind tyrosine kinases. Grb14 inhibits insulin receptor (IR) catalytic activity through interaction with the BPS domain and impedes peptide substrate binding. Members of this Grb family have also been shown to interact with other kinases through their SH2 domain. Here we examined the functional role of Grb14 in thyroid cancer using loss-and gain-of-function approaches. Stable knockdown of Grb14 in thyroid cancer cells facilitated IR signaling. In contrast, RET phosphorylation was diminished in concert with reduced activation of Akt and signal transducer and activator of transcription 3 (STAT3). Loss of Grb14 also resulted in diminished cell proliferation and invasion both in vitro and in mouse flank xenografts. In complementary studies, forced expression of Grb14 interrupted IR signaling but facilitated RET activation, STAT3 and Akt phosphorylation. Consistent with these findings Grb14 overexpression enhanced cell invasion and resulted in striking metastases in an orthotopic thyroid cancer mouse xenograft model. Primary human thyroid
Introduction
Thyroid cancers represent a heterogeneous group of endocrine malignancies. During the development of epithelial thyroid cancers, the RET proto-oncogene has an important role in tumor initiation and progression (Kondo et al., 2006) . RET is responsible for normal development of the neural crest-derived cell lineages (Avantaggiato et al., 1994) , regulating cell proliferation, migration and differentiation in response to its activation by a co-receptorligand complex (Durbec et al., 1996) . Gain-of-function mutations or rearrangements of RET lead to constitutive activation of this tyrosine kinase receptor, which in turn causes the up-regulation of oncogenic signaling pathways (Asa, 2001) leading to medullary or papillary thyroid cancer development. It has been shown that the level of phosphorylation of the different tyrosine residues outside the kinase domain may also regulate downstream signaling to influence proliferation, morphogenesis and tumor formation (Buckwalter et al., 2002) .
The growth factor receptor-bound (Grb) family of adaptor proteins (Grb7/10/14) has been characterized by a unique Between Plekstrin and SH2 (BPS) domain that facilitates avid binding to activated insulin receptor (IR) tyrosine kinases (Margolis, 1994) . Grb14, the most restricted member of this family, is known to interrupt IR signaling through binding to the activation loop. In so doing, it impedes downstream IR signaling (Kasus-Jacobi et al., 1998) , thus having a crucial role in the regulation of IR function. However, other receptor tyrosine kinase (RTKs) have also been shown to interact with members of this Grb family. In particular, RET is known to interact with Grb7 and Grb10 (Pandey et al., 1995 (Pandey et al., , 1996 . The functional impact of this interaction, however, has not been examined, nor is the role of Grb14 in thyroid cancer progression known.
The aim of this study was to examine the effect of Grb14 on receptor signaling and thyroid cancer progression. To this end, we tested the impact of Grb14 on the IR as a recognized target, and RET as a putative target of Grb14 action. Using complementary loss-and gain-offunction approaches, we examined the functional impact of Grb14 on thyroid cancer cell growth, invasiveness and metastasis. To determine the significance of the results in human disease, we used a tissue microarray of human thyroid carcinomas to validate the relationship between Grb14 and behavior of this neoplasm.
Results
Establishing stable Grb14 knockdown and overexpressing thyroid cancer cells To establish a system to examine the impact of Grb14 in thyroid cancer, we screened a panel of human thyroid carcinoma-derived cell lines for their endogenous expression of this adaptor protein (Figures 1a and b) . Further, given the known role of the RET tyrosine kinase in thyroid cancer we also examined co-expression of this kinase. This survey identified WRO and TPC-1 cells as expressing Grb14 and the RET/PTC1 (papillary thyroid carcinoma-1) re-arrangement (Figures 1a-c) . Treatment of these cells with glial derived nerve factor failed to stimulate RET phosphorylation, confirming their lack of the wild-type RET extracellular domain (data not shown). These two cell lines were selected for the creation of multiple clones with stable knockdown of the Grb14 adaptor to understand its functions (Figure 1d ).
Grb14 knockdown facilitates IR signaling but impairs RET activation
To examine the functional impact of Grb14, we first examined the responsiveness of the IR as a wellrecognized target of Grb14 action. In WRO cells, reduction of Grb14 predictably enhanced IR phosphorylation evidenced by increased pY972 and within the kinase domain pY1158/1162 of the receptor (Figure 2a ). In contrast, RET phosphorylation was diminished when Grb14 was reduced (Figure 2b ; Supplementary Figure S1 ). Consistent with diminished RET signaling, pMAPK ( Figure 2b ) was also attenuated in response to Grb14 reduction. To further corroborate the attenuation of RET signaling, we examined two downstream RET targets. Figure 2c demonstrates diminished pY-signal transducer and activator of transcription 3 (STAT3) in response to Grb14 reduction. Akt phosphorylation, another RET signaling target, was measurably impaired in Grb14-reduced cells (Figure 2d ). To examine these Grb14 signaling properties in an alternate thyroid cancer cell line, we examined Grb14 downregulated TPC-1 cells. Again we noted that forced reduction of Grb14 resulted in increased IR phosphorylation. As with WRO cells, RET phosphorylation was diminished in the face of downregulated Grb14 in TPC-1 cells (Supplementary Figure S2) . Similarly, Akt activation was attenuated in the face of Grb14 reduction in TPC-1 cells (Supplementary Figure S2) .
Grb14 knockdown impairs thyroid cancer cell proliferation and invasion in vitro and in vivo To test the impact of dysregulated receptor signaling, we examined the role of Grb14 reduction on cell proliferation. WRO cells stably downregulated for Grb14 revealed altered cell polarity as depicted in phasecontrast photomicrographs (Figure 3a) . Consistent with this altered morphological appearance, WRO/shGrb14 grew more slowly (Figure 3b ) and invaded matrigel membranes with diminished efficiency (Figure 3c ) compared with control cells stably transfected with scrambled shRNA sequence (WRO/scramble). Similar impact of Grb14 reduction on TPC-1 cell proliferation was also noted (data not shown).
To assess the impact of Grb14 reduction on tumor progression, we used a flank xenograft model in severe combined immunodeficient (SCID) mice that allows accurate analysis of tumor growth (Figure 3d ). Reduced Grb14 impaired thyroid cancer progression wherein WRO/shGrb14 tumors appeared later and grew significantly more slowly than controls (WRO/scramble; Figure 3e ). Histological examination revealed less invasive growth and lower proliferation as determined by lower mitotic counts (6% vs 16%) and Ki-67 labeling indices (18% vs 47%). No impact on apoptosis was noted by terminal deoxynucleotidyl transferase TDTmediated deoxyuridine-triphosphate nick-end labeling Diminished cell proliferation is noted during growth-curve measurements in response to Grb14 reduction. The summation of three independent proliferation assays demonstrates the significant difference between the proliferation rates of scrambled (WRO/scramble) and knockdown clones (WRO/shGrb14) as shown in the panel to the right. The *denotes significance, where Po0.00005; Po0.00005 and Po0.0005 at 3, 5, and 7 days, respectively. (c) Representative membranes of a Matrigel Invasion assay demonstrate the reduction in invasiveness of Grb14 knockdown cells compared with their scrambled controls to the left. The mean from two independent experiments quantifies the impact of Grb14 reduction on impaired WRO cell invasion with significance depicted by an asterisk as determined by the MannWhitney U-test (P ¼ 0.028). (d) Photographs of flank xenografts demonstrate the slowed progression of tumor growth in SCID mice carrying Grb14 downregulated WRO cells (WRO/shGrb14) compared with their scramble (WRO/scramble) controls. Control tumors infiltrate and erode overlying skin, resulting in ulceration, whereas tumors with downregulation of Grb14 have pushing borders that do not erode overlying skin (hematoxylin-eosin stain). (e) This time course demonstrates the reduced rate of tumor development in Grb14 downregulated xenografts compared with scramble controls. The mean from two independent experiments quantifies the difference between tumor sizes, which was statistically significant throughout the experiment. The differences in tumor volumes and weights were significantly different as measured at the time of killing (*Po0.001; **Po0.01 on both panels).
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K Balogh et al (TUNEL) staining. Western blotting of lysates from excised tumors confirmed diminished p-Akt levels in response to Grb14 knockdown (data not shown). TPC-1 cells did not develop efficient xenografts and hence mouse studies could not be performed using these cells.
Grb14 overexpression impedes IR but promotes RET signaling
In complementary experiments we forced Grb14 expression in multiple clones of WRO and TPC-1 cells (Supplementary Figure S3A) , which resulted in higher The impact of Grb14 overexpression on cell proliferation is shown in a representative growth curve (left); a summary of two independent proliferation assays depicts the significant difference between control (WRO/control) and Grb14 overexpressing (WRO/Grb14) cells as indicated. Proliferation rate was determined every day as a percentage of the average of controls. The *symbol denotes a highly significant Mann-Whitney test (Po0.000001); **significant with Mann-Whitney test (P ¼ 0.0325). (c) An orthotopic mouse xenograft model demonstrates the rapid progression of disease in mice inoculated with Grb14 overexpressing cells compared with their controls. Tumors overexpressing Grb14 (T) infiltrate into surrounding structures, including salivary gland (S) and skeletal muscle (M) (hematoxylin-eosin stain). (d) The growth curve displays the significantly faster growing tumors in Grb14 overexpressing clones compared with empty vector controls. The differences between tumor xenografted tissues shows larger volumes and greater weights in the Grb14 overexpressing group compared with empty vector clones. The *symbol denotes highly significant differences (Po0.001 at days 5, 9, 11 and tumor volume at killing); **denotes significance (Po0.01 at days 7, 13, 15, and tumor weights at killing) with Mann-Whitney test. (e) At autopsy, the lungs of animals bearing control cells exhibited small foci of metastatic carcinoma (left, arrow), whereas those with tumors overexpressing Grb14 (middle) had huge metastatic deposits with tumor thrombi in vessels (V) and metastatic malignant pericardial disease surrounding the entire heart (right, arrows), a feature that was not seen in any other animals (hematoxylin-eosin staining). In contrast, 10/10 mice in the WRO/Grb14 group developed multifocal pulmonary metastases (total of 70 metastatic foci) that collectively measured 612 057 mm 2 . In addition, calcified liver metastases were evident in 2/ 10 animals in the Grb14-overexpressing group. Massive malignant pericardial involvement was also seen in response to forced Grb14 expression (Figure 5e far right). In addition, western blotting of tumor lysates confirmed increased Akt phosphorylation in response to Grb14 overexpression (data not shown).
Grb14 expression correlates with human thyroid cancer invasiveness
To explore the relevance of our findings to clinical thyroid cancer behavior, we examined expression of this adaptor in primary tissue microarrays. Primary human thyroid samples of well-differentiated thyroid cancer (n ¼ 203), their respective normal tissues, and lymph node metastases (n ¼ 35) were used for tissue microarray construction and immunohistochemical expression of Grb14 (Figures 6a and b) . Staining intensity and distribution scores were derived from software image analyses as previously described (Cheng et al., 2009 (Cheng et al., , 2011 . This approach identified a positive staining score correlating Grb14 positivity and the presence of lymph node metastases (Figure 6c) . The relationship between Grb14 and behavior was evident in both classic papillary thyroid carcinoma (PTC; n ¼ 162) and in follicular variant-papillary thyroid carcinoma (FV-PTC; n ¼ 41). In addition, Grb14 expression correlated positively with the thyroid cancer biomarker HBME-1 (r ¼ 0.192; P ¼ 0.042).
Discussion
Grb14 is an adaptor protein recognized for its ability to interact with tyrosine kinase receptors, including the IR (Bereziat et al., 2002; Nouaille et al., 2006) , the fibroblast growth factor receptor 1 (Reilly et al., 2000) , and the platelet-derived growth factor receptor (Daly et al., 1996) . Nevertheless, most functional studies have focused on the ability of Grb14 to interrupt IR signaling through binding to its activation loop. This interaction protects the IR from de-phosphorylation but also impairs peptide substrate recruitment to diminish insulin-mediated signaling (Han et al., 2001) . Consistent with this model, Grb14-deficient mice are noted for their ability to evade insulin resistance (Cooney et al., 2004) . However, considerably less, is known about the role of Grb14 in neoplastic conditions. Here we show for the first time the ability of Grb14 to modulate the RET pathway to significantly control thyroid cancer behavior.
Grb 7 and 10, the two other members of the Grb7/10/ 14 family associate with RET through their SH2 domains (Pandey et al., 1995 (Pandey et al., , 1996 . Of note, transcriptomic analyses of NIH-3T3 cells harboring activating RET mutations revealed upregulation of Grb14 expression (Engelmann et al., 2009) . These findings and the recognized structural predictions for Grb14 interactions prompted us to investigate the role of this adaptor using thyroid cancer as a model. The key importance of RET in thyroid cancer pathogenesis (de Groot et al., 2006) supported our focus on this disease as a model of Grb14 action in cancer behavior. Indeed, our examination of primary human thyroid carcinoma tissue microarrays identified a positive correlation between the expression of Grb14 and tumor metastasis into the lymphatics. Clearly, additional studies will now be required to determine the extent to which Grb14 expression promotes the behavior of different types of thyroid cancers that rely on distinct signaling pathways.
To investigate the role of Grb14 levels on thyroid tumor behavior, we stably introduced Grb14 knockdown or overexpression to study cell proliferation and invasion in vitro and in vivo. As our first observations, we detected changes in cell polarity and architecture in response to Grb14 reduction. This was associated with diminished cell proliferation and impaired invasion into matrigel chambers. When introduced in mouse xenografts, thyroid cancer cells with reduced Grb14 grew significantly more slowly and displayed attenuated Figure 6 Tissue microarray analysis demonstrates a correlation between Grb14 expression and human thyroid cancer invasiveness. A tissue microarray (TMA) of human thyroid carcinomas including 162 PTC and 41 FV-PTC was stained for Grb14. (a) Two representative papillary carcinomas exhibit markedly different staining for Grb14; the tumor on the left exhibited extra-thyroidal extension and multiple lymph node metastases, whereas the tumor on the right (b) was localized to thyroid. (c) Image analysis confirmed a significant correlation between expression of the Grb14 adaptor and the presence of lymph node metastases . Comparisons were performed using the Wilcoxon rank sum test.
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K Balogh et al invasive properties. Conversely, Grb14 overexpression resulted in strikingly enhanced oncogenic behavior evidenced by multiple measures. In particular, Grb14 gain resulted in an invasive phenotype, which included not only accelerated tumor growth but also marked metastatic features. Reminiscent of the human form of the disease, Grb14 excess promoted metastasis into the lungs and surrounding structures. Grb7 and 10 have been reported to similarly facilitate tumor formation in ovarian and breast cancer models (Bai and Luoh, 2008; Sullivan et al., 2008; Wang et al., 2010) . Moreover, overexpression of Grb14 has been described in clear cell ovarian cancer (Marchini et al., 2008) and RETmutation associated thyroid tumor xenografts (Engelmann et al., 2009) , but the molecular mechanism remains unclear. Further, the metastatic phenotype acquired through Grb14 shown here has not, to our knowledge, been previously described. The molecular basis underlying the impressive phenotypic features associated with Grb14 remains poorly understood. We first examined the phosphorylation state of the IR in the context of Grb14 manipulations. Consistent with the high affinity of Grb14 binding through its unique BPS domain to the activation loop of the IR (Nouaille et al., 2006) , we showed that Grb14 knockdown predictably facilitates signaling through the IR. In contrast and consistent with the key role of RET in thyroid cancer (Kondo et al., 2006) , Grb14 knockdown diminished RET phosphorylation at Y905 (corresponding to Y294 in RET/PTC1). This finding is of functional relevance for several reasons. First, RET is a recognized docking site for Grb7 and Grb10 (Pandey et al., 1995 (Pandey et al., , 1996 . Indeed, mutation of this interaction site impairs RET/PTC1-mediated tumor formation in transgenic mice carrying the rearrangement (Buckwalter et al., 2002) . These RET mutant mice also show diminished Akt phosphorylation (Buckwalter et al., 2002) , a prominent feature we also identified in response to Grb14 manipulation on pAkt in the high-expressing WRO cells. Grb14 also attenuated pAkt responses in TPC-1 cells, which harbor this RET rearrangement. Akt is a key survival node in cell cycle progression and in RET-mediated transformation in thyroid cancer cells (Saji and Ringel, 2010) . Conversely, Grb14 overexpression supported activation of RET, an effect associated with augmented Akt activation. Although the involvement of other RTKs cannot be excluded, our data are consistent with Grb14 as one key regulator of Akt phosphorylation and function that is linked with thyroid cancer behavior.
STAT3 is a transcription factor that is classically activated through tyrosyl phosphorylation (Yu et al., 2009) . It is also a known target of RET signaling (de Groot et al., 2006) . Activation of STAT3 by RET/PTC1 results in enhanced cell proliferation and transformation (Hwang et al., 2003) . Thus, we have examined the STAT3 phosphorylation as a down-stream measure of Grb14-controlled RET signaling. Indeed, Grb14 knockdown impaired STAT3 activation in concert with diminished RET phosphorylation. Consistent with this finding Grb14 overexpression resulted in strong STAT3 activation. Taken together, our findings implicate Grb14 in modulating multiple tyrosine kinases. This leads to a signaling repertoire that impedes or augments an oncogenic phenotype. Importantly, the restricted pattern of expression and the strong phenotypic impact of Grb14 predict an important role for this adaptor in modulating cancer progression.
In summary, we have identified that the growth receptor-bound protein 14 is an important regulator of thyroid cancer behavior. We have shown that loss of Grb14 slows down the proliferation of thyroid tumor cells and interrupts their invasive properties. In contrast, overexpression of this adaptor protein significantly enhances thyroid cancer growth, invasiveness, and metastatic behavior. We also show, for the first time, the ability of Grb14 to alter RET signaling and that forced under-or overexpression of Grb14 modulates cell proliferation and invasion in an Akt/STAT3-coordinated manner. The contrasting impact of Grb14 on receptor signaling suggests an important role for this adaptor in modulating the balance over multi-RTKmediated responses. Given the increasingly recognized role of docking proteins in modulating the response to pharmacological RTK inhibition (Saji and Ringel, 2010) , it remains to be seen whether this feature is shared with members of the Grb7/10/14 adaptor family.
Materials and methods

Cell lines and cell culture
Human thyroid carcinoma-derived cell lines TT (ATCC, Manassas, VA, USA), WRO-82-1 (established by Dr GJF Juillard, University of California-Los Angeles School of Medicine, Los Angeles, CA, USA), TPC-1 (provided by Dr SM Jhiang, Ohio State University, Columbus, OH, USA), 8505C (Cell Resource Center for Biomedical Research, Tohoku University, Sendai, Japan) and KTC-1 (established by Dr J Kurebayashi, Kawasaki Medical School, Okayama, Japan) were maintained in RPMI 1640 with streptomycin sulfate (100 mg/l) and penicillin G sodium (100 mg/l), and supplemented with 10% fetal bovine serum (FBS; Life Technologies, Burlington, ON, Canada).
Stimulation studies
Following serum deprivation in RPMI 1640, cells were cultured in RPMI supplemented with 10% FBS, as a source of multiple growth factors, or maintained in serum-free growth medium without or with insulin (300 nM) or glial-derived nerve factor (R&D Systems Minneapolis, MN, USA; 50 ng/ml) for up to 30 min as indicated. Identical volume of vehicle served as a control.
Stable Grb14 knockdown and forced expression Grb14 was stably downregulated using the SureSilencing shRNA plasmid system (SABiosciences, Frederick, MD, USA). Control clones were transfected with scrambled sequences according to the manufacturer's instructions. To establish Grb14 overexpression, cells were transfected with Grb14 or empty vector (generously provided by R Daly) as described (Daly et al., 1996) . Plasmids were introduced using GeneJuice transfection reagent (Novagen, EMD Chemicals Inc., Merck, Darmstadt, Germany). Stably transfected clones were selected using 1000 mg/ml G418 (Multicell Technologies, Woonsocket, RI, USA) and maintained with G418 (500 mg/ml) during the experiments. At least two independent experimental clones and two independent control clones were used in each experiment.
RNA extraction and reverse transcriptase (RT) PCR Total RNA was isolated from cultured cells using RNeasy Kit (Qiagen, Valencia, CA, USA), followed by DNase I treatment. RT reactions were performed from 2 mg total RNA in 20 ml final volume using High Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Carlsbad, CA, USA). Specific PCR primers for Grb14, extracellular domain of RET (RET-EC) or the tyrosine kinase domain of RET (RET-TK) was used (Supplementary Table S1 ). Amplification was performed using HotStarTaq DNA polymerase kit (Qiagen). The PCR protocol started with a 15-min activation at 95 1C, followed by 35 cycles of denaturation at 94 1C (30 s), an annealing step at a specified temperature between 55 and 65 1C (30 s), and extension at 72 1C (1 min). The final extension was performed at 72 1C for 10 min. Negative controls omitting RT were included in each PCR reaction.
Cell lysates and western blotting Cultured cells were lysed in an immunoprecipitation buffer (0.5%. sodium deoxycholate, 0.1% sodium dodecyl sulfate, 1% Nonidet P-40 and 1x PBS) containing proteinase inhibitors (100 mg/ml phenylmethylsulfonyl fluoride, 13.8 mg/ml Aprotinin (Sigma, St Louis, MO, USA) and Phosphatase Inhibitor Cocktail 2 (Sigma) 10 ml/ml). Xenografted tissues were lysed in the same lysis buffer after homogenization using a polytron homogenizer. Total cell lysates were incubated on ice for 30 min followed by microcentrifugation at 10 000 g for 15 min at 4 1C. Equal amounts (50 mg) of protein were separated by 10% SDS-polyacrylamide electrophoresis and transferred onto nitrocellulose membranes, which were blocked in blocking buffer (10% nonfat milk and 0.1% Tween 20 in TBS (20 mmol/l Tris-Cl and 500 mmol/l NaCl (pH 7.5)) for 1 h and incubated overnight at 4 1C with primary antibodies, at optimized dilutions, as follows: anti-Grb14 (Millipore; 1:1000; Novus Biologicals, Oakville, ON, Canada, 1:500; Santa Cruz Biotechnology, Santa Cruz, CA, USA, 1:1000), anti-IR pY972 (Invitrogen, Grand Island, NY, USA, 1:1000), anti-IR pY1158/1162 (Invitrogen, 1:1000) and (Santa Cruz Biotechnology, 1:1000), anti-IRb (Cell Signaling, Boston, MA, USA, 1:1000), anti-actin (Sigma, 1:2000) , anti-GAPDH (Sigma, 1:2000) , anti-RET pY905 (Cell Signaling, 1:500), anti-RET pY1062 (Santa Cruz Biotechnology, 1:1000), anti-RET (Cell Signaling, 1:1000), anti-pMAPK (Sigma, 1:1000), anti-MAPK (Sigma, 1:2000), anti-pAkt S473 (Cell Signaling, 1:500), anti-Akt (Cell Signaling, 1:1000), anti-pY705-STAT3 (Cell Signaling, 1:500), and anti-STAT3 (Cell Signaling, 1:1000). Membranes were washed three times with washing buffer (TBS containing 1% Tween 20 and incubated with horseradish peroxidaseconjugated goat anti-rabbit or anti-mouse secondary antibody (Santa Cruz Biotechnology, 1:2000) for 1 h at room temperature. Protein bands were visualized using a chemiluminescence detection system (Amersham, Piscataway, NJ, USA). Band intensities were measured by scanning densitometry for quantification of the signals and the phosphorylated/total target ratio was expressed as a percent.
Invasion assay
Invasion assays were performed using BioCoat Matrigel Invasion Chambers (BD Biosciences Mississauga, ON, Canada). After 18 h of serum deprivation, 5 Â 10 4 cells were suspended in 0.5 ml of serum-free RPMI 1640 and plated into each insert, then wells in the plate were filled with RPMI 1640 supplemented with 10% FBS. After 20 h of incubation, noninvading cells were removed from the upper surface of the membrane by a cotton swab. Invaded cells on the lower surface of the membrane were stained with Diff-Quick Stain Solutions (BD Biosciences). After air-drying, the membranes were removed from the insert; invaded cells were photographed using a Slide Scanner and quantified with the APERIO ImagePro software (Vista, CA, USA).
Cell proliferation assay 1 Â 10 5 cells were seeded in 10 cm plates in RPMI 1640 media. Four plates were seeded for each clone for complete cell counting. Total cell counts were measured on day 3, 5 and 7 after seeding using a Vi-Cell Cell Viability Analyzer (BeckmanCoulter, Inc, Brea, CA, USA).
Human thyroid cancer cell xenografts WRO cells (4 Â 10 6 ) under-or overexpressing Grb14 or their controls were xenografted in the flanks or orthotopically implanted in the neck of 5-to 6-week-old SCID mice for assessment of tumor growth and metastasis. Animal handling and treatment protocols were approved by the Ontario Cancer Institute Animal Care and Utilization Committee. Tumor growth and volume were measured using calipers every other day (tumor volume in mm 2 ¼ tumor width Â tumor length). Mice were killed on day 15 after inoculation, at which point tumors were excised, weighed, and measured (tumor volume in mm 3 ¼ tumor width Â tumor length Â tumor depth/2) and full autopsies were performed. Excised tumor, lung and liver tissues and any other abnormal tissues were fixed in formalin and embedded in paraffin for light microscopy and immunohistochemistry.
Immunohistochemistry, TUNEL assay and primary human tissues Tissue blocks were fixed in formalin and embedded in paraffin for routine histology and immunohistochemistry. Paraffin sections 5 mm thick were de-waxed in xylene and hydrated through graded alcohols (Ezzat et al., 2002 (Ezzat et al., , 2005 . Immunoreaction of primary antibodies was detected by the avidinbiotin technique and visualized with 3,3 0 -diaminobenzidine. Cell apoptosis was determined using the TUNEL technique (ApopTag kit, Oncor, Integen Company, Purchase, NY, USA).
A human thyroid cancer tissue micro-array was built using cases of well-differentiated human thyroid carcinomas, including triplicate cores for every case and tissue type as described previously (Liu et al., 2007; Briese et al., 2010) . Immunohistochemical detection of Grb14 was standardized using positive and negative controls according to the manufacturer (Santa Cruz) and assessed under light microscopy by an endocrine pathologist to confirm appropriate tissue reactivity of the stain. Immunoreactivities were then evaluated by automated analysis using specific algorithms for each compartment as previously described (Cheng et al., 2009 (Cheng et al., , 2011 .
Statistical analysis
Continuous data are presented as mean ± s.e., although binomial variables are presented as absolute numbers and percent frequency. Results were analyzed using non-parametric statistical analysis, Mann-Whitney U-test when appropriate for comparison of median values of two independent groups. Statistical significance was achieved at two-tailed Po0.05.
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